Coloplast’s Q2 Earnings Decline Forces 10–15% Valuation Cut: What Investors Must Know
Coloplast’s latest quarter shows earnings dip and goodwill write‑down, prompting banks to cut price targets and re‑evaluate the Kerecis acquisition’s upside.
2 minutes to read
